Inclusion Criteria

DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian
tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis
from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have
ascites and tumor accessible by laparoscopic or percutaneous biopsy Immunohistochemical
evidence of p53 gene mutation in the ascitic fluid cell block or primary tumor biopsy or
other documented mutation

PATIENT CHARACTERISTICS: Age: 18 and over Life expectancy: At least 3 months Performance
status: Karnofsky 60-100% Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count
at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5
mg/dL AST/ALT less than 1.5 times the upper limit of normal (ULN) Alkaline phosphatase
less than 1.5 times ULN Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance
greater than 50 mL/min Other: Ability to tolerate paired paracenteses or biopsies
(percutaneous or laparoscopic) HIV negative No adenoviral infections determined by ELISA
screening No uncontrolled serious bacterial, viral, fungal or parasitic infection No known
or suspected hypersensitivity to study drug or any excipient used in formulation or
delivery system No underlying medical condition that would obscure interpretation of
adverse events Not pregnant or nursing Fertile patients must use effective contraception
for at least 1 month before, during, and 6 months after study

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior biologic therapy
and recovered Chemotherapy: At least 3 months since local intraperitoneal antitumor
therapy directed against peritoneal carcinomatosis and recovered At least 1 month since
systemic chemotherapy for ovarian, fallopian tube, or peritoneal cancer or an unapproved
indication and recovered Endocrine therapy: At least 3 months since any systemic
corticosteroid therapy Radiotherapy: At least 1 year since prior total abdominal
radiotherapy Surgery: Not specified Other: At least 3 months since prior investigational
therapy and recovered At least 3 months since prior immunosuppressive therapy